Avinger, Inc. (AVGR)
| Market Cap | 92.34M |
| Revenue (ttm) | 9.06M |
| Net Income (ttm) | -22.15M |
| Shares Out | 91.44M |
| EPS (ttm) | -0.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $0.968 |
| Previous Close | $1.010 |
| Change ($) | -0.042 |
| Change (%) | -4.12% |
| Day's Open | 1.010 |
| Day's Range | 0.962 - 1.010 |
| Day's Volume | 1,128,112 |
| 52-Week Range | 0.214 - 2.670 |
Avinger Inc (NASDAQ: AVGR) has submitted a 510(k) application to the FDA for a new Pantheris clinical indication for the treatment of in-stent restenosis (ISR) in the lower extremity arteries. To submis...
REDWOOD CITY, CA / ACCESSWIRE / July 6, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for d...
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
REDWOOD CITY, CA / ACCESSWIRE / June 28, 2021 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for ...
REDWOOD CITY, CA / ACCESSWIRE / June 7, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for d...
REDWOOD CITY, CA / ACCESSWIRE / May 25, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for d...
REDWOOD CITY, CA / ACCESSWIRE / May 17, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for d...
13% Year-over-Year Revenue Growth Driven by Tigereye™ Commercial Launch and Pantheris SV Sales Growth REDWOOD CITY, CA / ACCESSWIRE / May 6, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medica...
Penny stocks to buy according to top Wall Street analysts The post 3 Hot Penny Stocks To Buy With Analysts Expecting Up To 383% appeared first on Penny Stocks to Buy, Picks, News and Information | Penny...
REDWOOD CITY, CA / ACCESSWIRE / April 26, 2021 / Avinger, Inc. (NASDAQ:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for d...
List Of Penny Stocks To Watch Right Now The post Hot Penny Stocks To Watch In April 2021 If Biotech Is A Focus appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
REDWOOD CITY, CA / ACCESSWIRE / April 21, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for...
REDWOOD CITY, CA / ACCESSWIRE / April 15, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for...
REDWOOD CITY, CA / ACCESSWIRE / April 8, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for ...
It's been reported that AVGR stock is popular among Robinhood traders. That's fine, but it's more important to see the company's potential.
Avinger (NASDAQ:AVGR) reported Q4 results on Thursday afternoon. Quarterly Results Earnings per share were up 87.93% over the past year to ($0.07), which missed the estimate of ($0.06).
19% Sequential Increase in Total Revenue Tigereye™ Drives 38% Sequential Growth in Image-Guided CTO Revenue REDWOOD CITY, CA / ACCESSWIRE / March 11, 2021 / Avinger, Inc. (NASDAQ: AVGR), a commercial-st...
REDWOOD CITY, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire- Avinger, Inc. (Nasdaq: AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, ...
Avinger (NASDAQ:AVGR) announces its next round of earnings this Thursday, March 11. Here is Benzinga's everything-that-matters guide for this Thursday's Q4 earnings announcement.
REDWOOD CITY, CA / ACCESSWIRE / March 2, 2021 / Avinger, Inc. (NASDAQ:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for di...
Avinger (AVGR) stock is on the rise Thursday despite there being no new news from the company but chatter about a patent on social media. The post AVGR Stock: The Social Media Buzz That Has Avinger Shar...
19 New U.S. and International Patents Issued and Allowed in 2020 REDWOOD CITY, CA / ACCESSWIRE / January 19, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the f...
Avinger (AVGR) stock is taking off on Friday after announcing the full commercial release of its Tigereye medical device. The post AVGR Stock: 11 Things to Know About Avinger as Shares Rocket Higher app...
REDWOOD CITY, CA / ACCESSWIRE / January 15, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system f...
Avinger (AVGR) is seeing a massive boost to its stock on Friday after being listed as a hot penny stock to buy on Robinhood. The post AVGR Stock: 6 Things to Know About ‘Robinhood's Hot Penny Stock to B...
REDWOOD CITY, CA / ACCESSWIRE / January 6, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis an...
REDWOOD CITY, CA / ACCESSWIRE / December 23, 2020 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis ...
Avinger's (AVGR) CEO Jeff Soinski on Q3 2020 Results - Earnings Call Transcript
Avinger (AVGR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Avinger (AVGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Avinger (AVGR) news for Friday concerning approval from the FDA for one of its medical devices has AVGR stock on the move. The post Avinger News: AVGR Stock Down 8% Following FDA Approval appeared first...
Avinger's (AVGR) CEO Jeff Soinski on Q2 2020 Results - Earnings Call Transcript
Inside the top-ranked stocks that have been exhibiting rising price-to-earnings ratios.
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
There are pockets of the stock market that look far too overvalued to ignore, and our deep learning algorithms paired with our Artificial Intelligence (“AI”) technology has identified the top short targ...
Avinger (AVGR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Avinger, Inc. (AVGR) CEO Jeff Soinski on Q1 2020 Results - Earnings Call Transcript
Forget undervalued stocks, play these top-ranked stocks with rising P/E.
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Bet on these top-ranked stocks with rising P/E for outsized gains.
Avinger, Inc. (AVGR) CEO Jeffrey Soinski on Q3 2019 Results - Earnings Call Transcript
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Avinger (AVGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Top Ranked Momentum Stocks to Buy for October 24th
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
REDWOOD CITY, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD) today announced the closing of an...
REDWOOD CITY, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced the pricing of a...
REDWOOD CITY, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced that it intends ...
Avinger's (AVGR) CEO Jeff Soinski on Q2 2019 Results - Earnings Call Transcript
About AVGR
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as th... [Read more...]
| Industry Medical Devices | IPO Date Jan 30, 2015 |
| CEO Jeffrey Soinski | Employees 69 |
| Stock Exchange NASDAQ | Ticker Symbol AVGR |
Financial Performance
In 2020, Avinger's revenue was $8.76 million, a decrease of -4.05% compared to the previous year's $9.13 million. Losses were -$19.01 million, -2.28% less than in 2019.
Analyst Forecasts
According to 2 analysts, the average rating for Avinger stock is "Buy." The 12-month stock price forecast is 2.50, which is an increase of 158.16% from the latest price.